Navigation Links
Battelle Collaborating With Korean Partners to Advance Energy Efficiency and Health and Life Sciences Initiatives in Korea
Date:5/6/2008

COLUMBUS, Ohio, May 6 /PRNewswire-USNewswire/ -- Developing a strong pharmaceutical industry is a key issue in Korea. So much so, that Battelle-Korea, Battelle, Chuncheon City, Gangwon Province and YuYu Inc., intend to collaborate and address the issue. A Korean corporation named International Scientific Standard (ISS), Inc., will be formed to develop a bioequivalency business in Chuncheon City, Gangwon Province, that will meet international Good Laboratory Practices (GLP) standards.

ISS will perform studies that enable Korean pharmaceutical products to be certified by the U.S. Food and Drug Administration (FDA) and regulatory bodies in many countries around the world. This capability of ISS will enable pharmaceutical products developed by the Korean domestic companies to be sold in overseas markets, such as the U.S. and Europe.

In addition, the collaborators will work on developing energy efficiency technologies and buildings. They will work together to develop a roadmap toward greater energy efficiency in Gangwon Province. This roadmap will identify manufacturing, service, and research and development (R&D) opportunities.

"This is a very promising collaboration," said Joan Adams, President and CEO of Battelle Korea. "The opportunities to develop a stronger pharmaceutical industry, advance biotechnology initiatives, and provide greater energy efficiency can only be achieved through working cooperatively."

In attendance at the May 5 signing ceremony at Battelle's headquarters in Columbus, Ohio were: Joan Adams, Battelle Korea; Barbara Kunz, Battelle President for Health and Life Sciences Global Business; Seungpil Yu, Chairman and CEO of YuYu Inc., a; Jin-sun Kim, Governor of Gangwon Province, and Kwang Jun Lee, Mayor of Chuncheon City.

YuYu Inc. is a pharmaceutical company listed in the Korea Stock Exchange.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. It advances scientific discovery and application by conducting $4 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in more than 120 locations worldwide, including seven national laboratories which Battelle manages or co-manages for the U.S. Department of Energy and the U.S. Department of Homeland Security.

Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science and math education. For more information visit http://www.battelle.org or contact Media Relations Manager Katy Delaney at (410) 306-8638 or at delaneyk@battelle.org.


'/>"/>
SOURCE Battelle
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle
2. MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
3. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
4. Korean Food and Drug Administration Approval for ActiPatch Achieved
5. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 ... the "Company"), a biopharmaceutical company focused on the development and ... present at the 18 th Annual BIO CEO ... 10:00 a.m. EST in New York, NY ... CEO, will provide an update on the ongoing clinical trial ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
(Date:2/3/2016)... , Feb. 3, 2016  With the growing ... cliff that is underway, therapies such as monoclonal ... a whole host of indications are in high ... in the development and production of these therapeutics. ... quality and high costs, novel approaches and novel ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences ... targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s ... therapeutics for Alzheimer’s. , Following on from the first misfolded Amyloid beta target ...
Breaking Biology Technology:
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
(Date:1/7/2016)... LONDON , Jan. 7, 2016 ... demand for biopharmaceutical products such as biologics and ... pressure to reduce healthcare expenditure, growing demand for ... growing aging population. Biosimilars are similar versions of ... with regards to their quality, safety, and efficacy. ...
Breaking Biology News(10 mins):